Detection of molecular signatures of homologous recombination deficiency in prostate cancer with or without BRCA1/2 mutations.

CONCLUSIONS: These findings may expand the number of cases likely to respond to PARP inhibitor treatment. Based on the HR-associated mutational signatures, 5-8 % of localized prostate cancer cases may be good candidates for PARP-inhibitor treatment (including those with BRCA1/2 mutations). PMID: 32071115 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32071115?dopt=Abstract

Source: Clinical Cancer Research - February 17, 2020 Category: Cancer & Oncology Authors: Sztupinszki Z, Diossy M, Krzystanek M, Börcsök J, Pomerantz MM, Tisza V, Spisák S, Rusz O, Csabai I, Freedman ML, Szallasi Z Tags: Clin Cancer Res Source Type: research